NCT06892522 - A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | Biotech Hunter

Enrollment

440

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

February 29, 2036

Study Completion Date

March 31, 2036

Conditions

Multiple Myeloma

Interventions

DRUG

Etentamig

Intravenous (IV) Infusion

DRUG

Lenalidomide

Oral Capsule

DRUG

Dexamethasone

IV Injection

DRUG

Daratumumab

Subcutaneous Injection

DRUG

Dexamethasone

Oral Tablet

DRUG

Carfilzomib

IV Infusion

Trial Locations (15)

2145

RECRUITING

Westmead Hospital /ID# 271880, Westmead

2444

RECRUITING

Port Macquarie Base Hospital /ID# 275925, Port Macquarie

2450

RECRUITING

Coffs Harbour Health Campus /ID# 272010, Coffs Harbour

3000

RECRUITING

Peter MacCallum Cancer Centre /ID# 272024, Melbourne

4101

RECRUITING

Icon Cancer Care - South Brisbane /ID# 271836, South Brisbane

5000

RECRUITING

Royal Adelaide Hospital /ID# 272629, Adelaide

6005

RECRUITING

The Perth Blood Institute - West Perth /ID# 272469, West Perth

27514

RECRUITING

University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill

80218

RECRUITING

Colorado Blood Cancer Institute /ID# 273129, Denver

91120

RECRUITING

Hadassah Medical Center-Hebrew University /ID# 271362, Jerusalem

3525408

RECRUITING

Rambam Health Care Campus /ID# 271364, Haifa

4941492

RECRUITING

Rabin Medical Center /ID# 271365, Petah Tikva

5265601

RECRUITING

The Chaim Sheba Medical Center /ID# 271366, Ramat Gan

602-8566

RECRUITING

University Hospital Kyoto Prefectural University of Medicine /ID# 275713, Kyoto

565-0871

RECRUITING

The University of Osaka Hospital /ID# 275791, Suita-shi